DermaBio

Novel approach to managing autoimmune diseases through skin surface protein profiling, integrating women’s physiological features into predictive medicine — an element often ignored in current models.
DermaBio is well positioned for strategic acquisition by a major diagnostics company or national lab network. Our platform aligns with key priorities: high-volume testing, clinical utility, payer value, and scalability across multiple autoimmune conditions. As we move toward CLIA certification and commercial pilots, we are building the foundation for seamless integration into existing lab workflows.